Slingshot members are tracking this event:

Global Blood Therapeutics' Phase 2a of GBT440 HOPE-KIDS 1 treating Sickle cell disease in children age 6-17: Updated data due at ASH December 11, 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
GBT Community voting in process

Additional Information

Additional Relevant Details One of the two oral presentations – updated data from the ongoing Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor – has been selected to be featured in an ASH press briefing.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 11, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2a, Gbt440, Hope-kids 1